CRT Capital Thursday morning ratings report included a coverage initiation by analyst Arlinda Lee on Oncogenex Pharmaceuticals OGXI with a Buy rating and price target of $20.
The highlight for OGXI includes phase 3 trials of Curtisen and subsequent partnership with Teva, along with phase 2 trials of Apatorsen.
The report notes "The basis for our Buy rating is our optimism for a positive outcome from ongoing pivotal Phase 3 SYNERGY trial in castrate resistant prostate cancer (CRPC) in mid-2014. We expect FDA filing in 2H14 and approval in 20145. We also expect rapid uptake of custirsen to reach peak 35% penetration the US and 30% in EU."
OGXI closed the previous trading session at $11.51 and is currently trading around the $11.76 mark.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in